# Tag: Latache

- [Latache rejects terms of Oncoclínicas debt restructuring, favors court-supervised process](https://brazilstockguide.com/insights/latache-rejects-terms-of-oncoclinicas-debt-restructuring-favors-court-supervised-process/) (2026-10-14): Asset manager says proposed terms are overly favorable to creditors, has no seats on the board and questions the direction of the Brazilian cancer care provider’s financial restructuring.
- [Wald family-linked fund seeks another Oncoclínicas board overhaul](https://brazilstockguide.com/insights/wald-family-linked-fund-seeks-another-oncoclinicas-board-overhaul/) (2026-09-30): UBS Lumen, which owns 4.93% of the company, wants to replace five of seven directors as the cancer-care group faces financial strain and a deepening shareholder dispute.
- [Lawsuit Seeks Compensation for Oncoclínicas Shareholders After CVM Ruling](https://brazilstockguide.com/insights/oncoclinicas-shareholder-lawsuit-cvm-tender-offer/) (2026-09-29): Case seeks compensation for current and former investors and gains significance after Brazil’s securities regulator ruled that a corporate reorganization triggered a mandatory tender offer.
- [Oncoclínicas calls shareholder meeting after Latache seeks suspension of Josephina III rights](https://brazilstockguide.com/insights/oncoclinicas-latache-josephina-rights-tender-offer/) (2026-09-24): Funds want to temporarily suspend shareholder rights held by the Centaurus-linked vehicle until it complies with a mandatory tender offer ordered by Brazil’s securities regulator.
- [The Billion-Real Tender Offer Hidden in Oncoclínicas’ Bylaws](https://brazilstockguide.com/insights/the-billion-real-tender-offer-hidden-in-oncoclinicas-bylaws/) (2026-08-28): Brazil’s securities regulator has ordered Centaurus and Josephina III to launch the offer, but the price still depends on four formulas that could produce radically different outcomes.
- [BREAKING NEWS: CVM board unanimously finds Oncoclínicas tender-offer trigger was met](https://brazilstockguide.com/insights/breaking-news-cvm-board-unanimously-finds-oncoclinicas-tender-offer-trigger-was-met/) (2026-08-25): Dispute involves a potential offer estimated at about R$6 billion; the board sided with Latache and overturned the interpretation that had favored Centaurus following the acquisition of Goldman Sachs-held shares.
- [Centaurus Takes Oncoclínicas Dispute to Arbitration Ahead of CVM Ruling That Could Trigger a Multibillion-Real Bill](https://brazilstockguide.com/insights/centaurus-oncoclinicas-arbitration-cvm-tender-offer/) (2026-08-23): Move comes on the eve of a decision by Brazil’s securities regulator on a potential mandatory tender offer and could foreshadow a second battle: who pays, who gets paid and how much the offer is worth.
- [CVM board to have final say on Oncoclínicas tender offer after SRE stands by ruling](https://brazilstockguide.com/insights/cvm-board-to-have-final-say-on-oncoclinicas-tender-offer-after-sre-stands-by-ruling/) (2026-08-14): Latache’s appeal will be decided by three members of the regulator’s board; Marina Copola has recused herself from the case.
- [Oncoclínicas Moves Toward Extraordinary Meeting That Could Oust Entire Board](https://brazilstockguide.com/insights/oncoclinicas-extraordinary-meeting-board-activist-shareholders/) (2025-12-11): Board minutes disclosed Thursday (Dec. 11) show activist funds with over 14% stake pushing for sweeping governance reset
- [Goldman Sachs Cuts Oncoclínicas Exposure to 9% After Capital Increase](https://brazilstockguide.com/insights/goldman-sachs-cuts-oncoclinicas-exposure-to-9-after-capital-increase/) (2025-11-27): Bank, once economically exposed to nearly 60% of the company, sees its position sharply diluted as the oncology group moves to deleverage.
- [Latache Moves to Oust Oncoclínicas Board in Full Overhaul Push](https://brazilstockguide.com/insights/latache-moves-to-oust-oncoclinicas-board-in-full-overhaul-push/) (2025-11-26): Shareholders holding 14.6% demand a full reset of ONCO3’s governance structure.
